NGS-based tissue and ctDNA assays, PCR, immunohistochemistry), evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to ...
NGS-based tissue and ctDNA assays, PCR, immunohistochemistry), evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
In this high-impact, field-based role, you will drive the adoption and growth of Signatera , Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera , Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera , Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera , Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
OR · On-site
Collaborate with the Chief Medical Officer and other Medical Directors in Oncology on the clinical development of ctDNA-based diagnostics. * Lead development and implementation of clinical strategies ...
Laboratory Director
$128K - $167K/yr
Solid understanding of Illumina sequencing platforms, liquid biopsy (ctDNA), and tissue-based CGP assays. * Strong familiarity with professional guidelines for somatic variant interpretation (e.g ...
Laboratory Director
$128K - $167K/yr
Solid understanding of Illumina sequencing platforms, liquid biopsy (ctDNA), and tissue-based CGP assays. * Strong familiarity with professional guidelines for somatic variant interpretation (e.g ...
Diagnostics-native fluency: deep, unassisted comfort discussing cell-free DNA (cfDNA), ctDNA dynamics, minimal residual disease (MRD), analytical vs. clinical validity, and decision-impact metrics.
Diagnostics-native fluency: deep, unassisted comfort discussing cell-free DNA (cfDNA), ctDNA dynamics, minimal residual disease (MRD), analytical vs. clinical validity, and decision-impact metrics.
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
This is a high-impact, tumor-specific role focused on accelerating the adoption and growth of Signatera-our groundbreaking, first-in-class MRD ctDNA test. As a COS, you'll act as a strategic field ...
Executive Director, Biomarkers (Remote)
Philadelphia, PA · On-site
$276K - $414K/yr
Fluency in multi‑omic data (genomics, transcriptomics, proteomics, metabolomics) and molecular assay platforms (IHC/ISH, NGS, PCR, flow cytometry, mass spec, ctDNA). * Experience designing ...
Executive Director, Biomarkers (Remote)
Philadelphia, PA · On-site
$276K - $414K/yr
Fluency in multi‑omic data (genomics, transcriptomics, proteomics, metabolomics) and molecular assay platforms (IHC/ISH, NGS, PCR, flow cytometry, mass spec, ctDNA). * Experience designing ...
Staff Machine Learning Scientist, Agentic AI
OR · On-site +1
Leveraging a proprietary data moat of over 250,000 oncology patients profiled with longitudinal ctDNA, WES/WGS, digital pathology, and EMR data, you will design and deploy production-grade autonomous ...
Staff Machine Learning Scientist, Agentic AI
OR · On-site +1
Leveraging a proprietary data moat of over 250,000 oncology patients profiled with longitudinal ctDNA, WES/WGS, digital pathology, and EMR data, you will design and deploy production-grade autonomous ...
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
In this high-impact, field-based role, you will drive the adoption and growth of Signatera, Natera's personalized molecular residual disease (MRD) ctDNA assay, helping clinicians monitor cancer and ...
New
Post-Doctoral Research Fellow - HBV Biomarkers and Liquid Biopsy
Boston, MA · On-site
$70K - $71K/yr
... ctDNA) and viral genomic analysis Integrate genomic, clinical, and imaging datasets to support biomarker development and validation Contribute to study design, data interpretation, manuscript ...
Post-Doctoral Research Fellow - HBV Biomarkers and Liquid Biopsy
Boston, MA · On-site
$70K - $71K/yr
... ctDNA) and viral genomic analysis Integrate genomic, clinical, and imaging datasets to support biomarker development and validation Contribute to study design, data interpretation, manuscript ...
Computational Associate II - Gerstner Center for Cancer Diagnostics
Cambridge, MA · On-site
$58K - $80K/yr
... DNA (ctDNA) within the Gerstner Center for Cancer Diagnostics and Broad Cancer Program. The Gerstner Center aims to develop blood biopsies, among other cancer diagnostics, that stand to benefit ...
Computational Associate II - Gerstner Center for Cancer Diagnostics
Cambridge, MA · On-site
$58K - $80K/yr
... DNA (ctDNA) within the Gerstner Center for Cancer Diagnostics and Broad Cancer Program. The Gerstner Center aims to develop blood biopsies, among other cancer diagnostics, that stand to benefit ...
Integrate advanced translational data modalities, ctDNA/ctRNA, single-cell sequencing, spatial transcriptomics, computational pathology, and multiplex imaging into Nurix's precision medicine
Integrate advanced translational data modalities, ctDNA/ctRNA, single-cell sequencing, spatial transcriptomics, computational pathology, and multiplex imaging into Nurix's precision medicine
Deep familiarity with the data types used across the research lifecycle: trial biospecimens, on-study PD/ctDNA/MRD reads, real-world evidence, population cohorts, and multi-modal omics (bulk and ...
Deep familiarity with the data types used across the research lifecycle: trial biospecimens, on-study PD/ctDNA/MRD reads, real-world evidence, population cohorts, and multi-modal omics (bulk and ...
Director, Oncology Data Science
Boston, MA · On-site
$194K - $305K/yr
Leverage advanced AI/ML approaches to integrate multi-modal data including RNAseq, WES, ctDNA, digital pathology, proteomics, immune activation assays, and liquid biopsies to discover biomarkers and ...
Director, Oncology Data Science
Boston, MA · On-site
$194K - $305K/yr
Leverage advanced AI/ML approaches to integrate multi-modal data including RNAseq, WES, ctDNA, digital pathology, proteomics, immune activation assays, and liquid biopsies to discover biomarkers and ...
Ctdna information
What are the applications of ctDNA?
For a role involving ctDNA, its primary applications include detecting and monitoring genetic mutations in cancer patients, enabling personalized treatment plans and early disease detection. ctDNA analysis is also used for assessing treatment response and identifying minimal residual disease, often requiring skills in molecular diagnostics and next-generation sequencing technologies.
What is it called when you work with DNA?
Working with DNA in a professional context is often called molecular biology or genetic research. Jobs in this field may involve techniques like DNA extraction, PCR, sequencing, and analysis, often requiring specialized training and laboratory skills.
What is the difference between Ctdna vs ctDNA?
| Aspect | Ctdna | ctDNA |
|---|---|---|
| Definition | Circulating tumor DNA (Ctdna) refers to tumor-derived DNA fragments found in the bloodstream. | Circulating tumor DNA (ctDNA) is the same as Ctdna, representing tumor DNA fragments in blood. |
| Usage | Used in cancer detection, monitoring treatment response, and minimal residual disease. | Used similarly for cancer detection, prognosis, and treatment monitoring. |
| Work Environment | Laboratories performing liquid biopsies and molecular diagnostics. | Same as Ctdna, in clinical labs and research settings. |
| Certifications | Requires molecular biology, genetics, or pathology certifications. | Same certifications as Ctdna, often overlapping. |
Both Ctdna and ctDNA refer to tumor-derived DNA fragments circulating in the blood, used interchangeably in clinical and research settings for cancer diagnostics and monitoring.
What are the top liquid biopsy companies?
Top liquid biopsy companies include Guardant Health, Foundation Medicine, and Biocept, which develop blood-based tests for cancer detection and monitoring. These companies often employ molecular diagnostics, next-generation sequencing, and require specialized skills in genomics and laboratory techniques. They are recognized for innovation in non-invasive cancer diagnostics and have FDA-approved or CE-marked tests.
What does ctDNA do?
ctDNA, or circulating tumor DNA, refers to small fragments of DNA released into the bloodstream by cancer cells. It is used in liquid biopsies to detect, monitor, and analyze tumors non-invasively, aiding in cancer diagnosis and treatment planning.
More about Ctdna jobs
What cities are hiring for Ctdna jobs? Cities with the most Ctdna job openings:
What states have the most Ctdna jobs? States with the most job openings for Ctdna jobs include:
What job categories do people searching Ctdna jobs look for? The top searched job categories for Ctdna jobs are:
Associate Director, Precision Medicine & Companion Diagnostics
Redwood City, CA • Hybrid
Other
Posted 22 days ago
Job description
The Opportunity:
Revolution Medicines is offering a highly visible opportunity for talented and motivated individual to join our Precision Medicine Companion Diagnostics team as an Associate Director, Companion Diagnostics within the Translational Medicine function, which supports CDx development across RevMed portfolio. Through both scientific and cross-functional leadership, individual is to implement global diagnostic strategies to enable and support the global development and commercialization of medically differentiated therapies. The successful candidate will have the opportunity to work in a fast-paced, highly collaborative environment and will be a key member of multidisciplinary development project teams.
Required Skills, Experience and Education:
Lead the development and implementation of diagnostic strategies through registration and launch for individual clinical studies and/or molecule program.
Direct the development, outsourcing and validation of clinically applicable in vitro diagnostic assays through the development lifecycle of molecules, including design, implement and oversee diagnostic testing and registration strategy and timely communication with key internal and external stakeholders.
Provide expertise to development project teams to ensure access to state-of-the-art approaches on appropriate diagnostic technologies (e.g. NGS-based tissue and ctDNA assays, PCR, immunohistochemistry), evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to the proposed companion diagnostic assay.
Oversee implementation of clinical trial assays at CRO laboratories for centralized testing supporting clinical trials. Monitors all scope or changes in study are timely implemented, including the development of the work order, costs and agreements.
Lead joint development teams between RevMed and Dx partners to ensure cross-functional alignment of overarching development, regulatory and commercialization strategy, successful fit for purpose CDx development and that co-development timelines are met.
Serve as subject matter expert in diagnostic regulation and support the interactions with global health authorities regarding companion diagnostics development and submissions.
Preferred Skills:
Highly experienced biomarker or diagnostics professional (MS and/or PhD) with a minimum of 7-10 years of relevant industry experience with expertise in oncology biomarker and/or companion diagnostic development.
High level of initiative and ability to work independently with business awareness, hands on experience in IVD development processes and global in vitro diagnostic regulatory aspects related to companion diagnostic development.
Experience with biomarker application in clinical trials and awareness of the challenges of implementing diagnostic technologies in the clinical setting.
Experience with health authority interactions and regulatory submissions for pharmaceutical and/or in vitro diagnostics development globally.
Excellent leadership skills including motivation and influencing without authority.
Highly collaborative team player who fosters open communication and facilitates mutual understanding and cooperation between all stakeholders with excellent communication, analytical and organizational skills.
Cross-functional experience in commercial and or medical aspects of companion diagnostics is a plus.
#LI-Hybrid #LI-EM1